Coeptis Therapeutics Hldgs I
13F holders, Q3 2024 (September 30)15holders −3
3new positions
6sold out
1famous investor
$0.18avg. 13F price*
At the end of Q3 2024, 15 institutions reported holding Coeptis Therapeutics Hldgs I in their 13F filings, down 3 from Q2 2024. 3 opened new positions and 6 sold out. The largest holders were Creative Planning ($116K), Meteora Capital, LLC ($80K) and Geode Capital Management, LLC ($28K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Coeptis Therapeutics Hldgs I
- CUSIP
- 19207A108
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $31K |
| Exits | 6 | $32K |
All 13F filers, Q2 2024 → Q3 2024: 187,834 shares bought and 158,972 shares sold, net +28,862 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Creative Planning | 0.00% | No change | 645,104 | $116K |
| Meteora Capital, LLC | 0.02% | No change | 446,251 | $80K |
| Geode Capital Management, LLC | 0.00% | Reduce -22.7% | 153,781 | $28K |
| Citadel Advisors | 0.00% | New | 111,338 | $20K |
| Vanguard Group Inc. | 0.00% | No change | 100,759 | $18K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | No change | 56,149 | $10K |
| Arista Wealth Management, LLC | 0.00% | No change | 47,332 | $9K |
| UBS Group AG | 0.00% | New | 38,975 | $7K |
| Jane Street Group, LLC | 0.00% | Add +124.8% | 31,565 | $6K |
| Steward Partners Investment Advisory, LLC | 0.00% | New | 20,000 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -0.7% | 9,574 | $2K |
| Mint Tower Capital Management B.V. | 0.00% | No change | 45,000 | $1K |
| Bank of America Corp. | 0.00% | Reduce -6.5% | 201 | $36 |
| Semmax Financial Advisors Inc. | 0.00% | No change | 112 | $23 |
| Barclays PLC | 0.00% | No change | 67 | $12 |
"% of holder's portfolio" is COEPTIS THERAPEUTICS HLDGS I's weight in each manager's 13F, not the share of Coeptis Therapeutics Hldgs I the manager owns.